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In cancer patients, anti-tumor functions of NK cells are
severely impaired by a variety of immunosuppressive
mechanisms. Interleukin (IL)-2 and -15 are two essential
cytokines regulating the development and function of
human natural killer (NK) cells. Here, we compared the
role of IL-2 and IL-15 to render resistance of human
NK cells to tumor-induced suppression. We found that
early-passage melanoma tumor cells strongly inhibited
functions of IL-2 activated NK cells through production
of prostaglandin E2 (PGE2). Under the same condition,
IL-15 activated NK cells could significantly retain the
ability to proliferate in vitro durability, in comparison to
IL-2-expanded cells. Altogether, our study uncovers dis-
tinct properties between IL-2 and IL-15 on primary
human NK cells under tumor-induced suppression. It
provides evidence that implementation of IL-15 may
greatly improve the clinical efficacy of adoptive NK cell
therapy for the treatment of human cancers.
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